Adagene ADR GAAP EPS of -$1.46, revenue of $10.2M

S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Adagene ADR GAAP EPS of -$1.46, revenue of $10.2M

To read the full story on Seeking Alpha, click here.

Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Adagene Charts.

Adagene (NASDAQ:ADAG)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Adagene Charts.

Adagene Inc News

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Friday 29 March 2024 (1 month ago) • GlobeNewswire Inc.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Thursday 7 March 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 9 February 2024 (3 months ago) • Edgar (US Regulatory)

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab
Friday 9 February 2024 (3 months ago) • GlobeNewswire Inc.

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Tuesday 16 January 2024 (3 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 16 January 2024 (3 months ago) • Edgar (US Regulatory)

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Thursday 4 January 2024 (4 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 3 November 2023 (6 months ago) • Edgar (US Regulatory)

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
Friday 3 November 2023 (6 months ago) • GlobeNewswire Inc.

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Thursday 12 October 2023 (7 months ago) • GlobeNewswire Inc.

More Adagene Inc News Articles

Global Developments (PK)

Yuenglings Ice Cream (PK)

FBEC Worldwide (PK)

Mullen Automotive

Elite Pharmaceuticals (QB)

CBD of Denver (PK)

Virexit Technologies (PK)

Tonner One World (PK)

Branded Legacy (PK)

International Star (PK)

Impact Fusion (PK)

BlueFire Equipment (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions